Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,748
  • Shares Outstanding, K 16,850
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,130 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0400 +29.81%
on 11/21/25
1.5600 -13.46%
on 11/10/25
-0.0800 (-5.59%)
since 11/05/25
3-Month
1.0400 +29.81%
on 11/21/25
2.7100 -50.18%
on 09/16/25
-0.2600 (-16.15%)
since 09/05/25
52-Week
1.0400 +29.81%
on 11/21/25
298.0000 -99.55%
on 12/12/24
-198.2500 (-99.32%)
since 12/05/24

Most Recent Stories

More News
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / September 5, 2025 / RedChip Companies will air interviews with Foremost Clean Energy Ltd. (NASDAQ:FMST) and Aptevo Therapeutics, Inc. (NASDAQ:APVO) on the RedChip Small...

APVO : 1.3500 (-2.88%)
FMST : 2.93 (-4.25%)
FAT.CN : 4.0700 (-5.13%)
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / August 8, 2025 / RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...

APVO : 1.3500 (-2.88%)
SXTP : 0.9734 (-0.68%)
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics...

APVO : 1.3500 (-2.88%)
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology...

APVO : 1.3500 (-2.88%)
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

VXF : 213.06 (-0.08%)
APVO : 1.3500 (-2.88%)
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics...

APVO : 1.3500 (-2.88%)
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care

APVO : 1.3500 (-2.88%)
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action

APVO : 1.3500 (-2.88%)
Aptevo to Participate in March Conferences

SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 1.3500 (-2.88%)
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth

APVO : 1.3500 (-2.88%)

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 1.4300
2nd Resistance Point 1.4100
1st Resistance Point 1.3800
Last Price 1.3500
1st Support Level 1.3300
2nd Support Level 1.3100
3rd Support Level 1.2800

See More

52-Week High 298.0000
Fibonacci 61.8% 184.5613
Fibonacci 50% 149.5200
Fibonacci 38.2% 114.4787
Last Price 1.3500
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar